

## Effect of the induced expression of human sprouty protein-1 (spry1) on SKOV-3 human ovarian cancer cells' proliferation, migration, invasion and survival *in vitro*

Samar Masoumi Moghaddam, Afshin Amini, Ai-Qun Wei and David Lawson Morris  
The University of New South Wales, Australia

**Introduction:** We have already shown that the expression of Spry1, a MAPK/ERK regulator, is significantly reduced in human ovarian cancer cell line SKOV-3. In this study, we investigated how Spry1 transfection could affect SKOV-3 cells' behaviour.

**Methods:** SKOV-3 cells were transiently transfected with the Spry1 plasmid or pcDNA3.1. The effect of the induced expression of Spry1 was investigated using proliferation, MTT, scratch-wound, migration and invasion assays. Stably-transfected clones were also selected to evaluate the effect of transfection on the cell survival.

**Results:** On day 3 post-transfection, the transfected cell proliferation was significantly lower than control evaluated by growth (p-value:0.0003) and MTT (p-value:0.0042) assays. In the migration assay, the number of migrated cells in the transfection group was significantly lower than control examined at hour 6 (p-value:0.0090) and 12 (p-value:0.0002). Similarly, our invasion assay showed a decreased number of invading cells in the Spry1 group assayed at hours 6 (p value:0.0159) and 12 (p-value:0.0005). Taken together, the invasion percentage of Spry1-transfected cells was significantly reduced at hours 6 and 12 (p-values of 0.0191 and 0.0021, respectively). Also, a significantly-decreased percentage of the scratch closure was observed in the Spry1 group viewed at hours 20 and 24 (p-values of 0.0232 and 0.0046, respectively). In our stable transfection setting, the Spry1-transfected selected clones were almost undetectable after day 14 post selection.

**Conclusion:** Here, we report that Spry1-transfected SKOV-3 cells proliferate, migrate, and invade significantly less than do the negative control cells, and that their stably-selected clones do not survive beyond 14 days of the selection.

### Biography

Samar Masoumi Moghaddam completed her medical degree in General Practice in 2005. Being interested in cancer research, she has received a competitive international postgraduate scholarship from the University of New South Wales, Sydney, Australia. As a member of Professor Morris's research team at St George Hospital, she is currently involved in some key projects aimed to develop novel approaches to cancer therapy.

samar.masoumi@gmail.com